AP
Aprea Therapeutics, Inc.
APRE · NASDAQ
$0.73 +0.21% (+$0.00)
1M +8.71%
Market Cap $9.05M
P/E Ratio -
Div. Yield -
ROE 46.72%
Bulios Fair Price
$0.91
24.6% upside
Current Price
$0.73
Undervalued Fair Value Overvalued
According to Bulios Fair Price, APRE is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/B 0.24x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 21.42%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 33.73%
ROE 46.72%
ROA 29.10%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 13.55x
Int. coverage N/A
Stability
29 /100
Unstable Beta 1.63x
EPS volatility 42.26%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about APRE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Oren Gilad
Employees
8
Headquarters
Boston
Upcoming events
11 NOV
Earnings
Upcoming earnings report